patients with hepatocellular carcinoma

OTHER2 trials

Sponsors

Assistance Publique - Hôpitaux de Paris, Faculty of Medicine, Chulalongkorn university

Conditions

Hepatocellular CarcinomaImmunogenicity and safety of SARS-CoV-2 vaccine in patients with hepatocellular carcinoma COVID-19, vaccine, hepatocellular carcinoma, SARS-CoV-2

Unknown Phase

Immunogenicity and safety of SARS-CoV-2 (COVID-19 virus) vaccine in patients with hepatocellular carcinoma

Active, not recruitingTCTR20210525005

Faculty of Medicine, Chulalongkorn universityImmunogenicity and safety of SARS-CoV-2 vaccine in patients with hepatocellular carcinoma COVID-19, vaccine, hepatocellular carcinoma, SARS-CoV-2

Start: 2021-06-01Target: 60Updated: 2026-08-03

Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma

TerminatedNCT05044676

Assistance Publique - Hôpitaux de ParisHepatocellular Carcinoma

Start: 2023-09-08End: 2025-09-22Updated: 2025-12-18